ArticleCureus2026
Median Pancreatectomy for Benign and Low-Grade Malignant Pancreatic Lesions: An 11-Year Single-Center Experience With Perioperative and Functional Outcomes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Median pancreatectomy (MP) is a parenchyma-sparing procedure for benign and low-grade malignant lesions of the pancreatic neck and body, with the potential to preserve endocrine and exocrine function. However, concerns regarding postoperative pancreatic fistula (POPF) have limited its widespread adoption. Methods This retrospective cohort study included 23 consecutive patients who underwent MP at a tertiary referral centre between January 2015 and December 2025. POPF was classified using the 2016 International Study Group of Pancreatic Surgery criteria, and long-term endocrine and exocrine function was assessed during follow-up. Results The mean age was 43.57 ± 15.05 years, and 91.3% of the patients were female. Common indications included cystic neoplasms (60.9%), neuroendocrine tumours (21.7%), and solid pseudopapillary neoplasms. Biochemical leak occurred in 60.9% of patients, and Grade B POPF occurred in 30.4%. Patients with Grade B POPF had a significantly longer hospital stay than those with biochemical leak (25.00 ± 15.41 vs. 14.29 ± 7.53 days, p = 0.039). No mortality was observed. At a median follow-up of 98 months (range, 4-130 months), only one patient (4.3%) developed new-onset diabetes, and none developed exocrine insufficiency. Conclusion MP is a safe and effective parenchyma-sparing procedure with excellent long-term preservation of pancreatic function, despite the high incidence of biochemical leak and Grade B POPF, which can generally be managed conservatively with appropriate clinical care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.